153 related articles for article (PubMed ID: 15014897)
41. Pharmacokinetics of butorphanol nasal spray in patients with renal impairment.
Shyu WC; Morgenthien EA; Barbhaiya RH
Br J Clin Pharmacol; 1996 May; 41(5):397-402. PubMed ID: 8735680
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics of ondansetron in patients with hepatic insufficiency.
Figg WD; Dukes GE; Pritchard JF; Hermann DJ; Lesesne HR; Carson SW; Songer SS; Powell JR; Hak LJ
J Clin Pharmacol; 1996 Mar; 36(3):206-15. PubMed ID: 8690814
[TBL] [Abstract][Full Text] [Related]
43. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment.
Thyrum PT; Wong YW; Yeh C
Prog Neuropsychopharmacol Biol Psychiatry; 2000 May; 24(4):521-33. PubMed ID: 10958148
[TBL] [Abstract][Full Text] [Related]
44. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects.
Joffe P; Larsen FS; Pedersen V; Ring-Larsen H; Aaes-Jørgensen T; Sidhu J
Eur J Clin Pharmacol; 1998 May; 54(3):237-42. PubMed ID: 9681666
[TBL] [Abstract][Full Text] [Related]
45. Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment.
Barbhaiya RH; Shukla UA; Greene DS
Eur J Clin Pharmacol; 1995; 49(3):221-8. PubMed ID: 8665999
[TBL] [Abstract][Full Text] [Related]
46. Effect of severe renal impairment on the pharmacokinetics and tolerability of the parenteral endothelin antagonist tezosentan.
van Giersbergen PL; Dingemanse J
Int J Clin Pharmacol Ther; 2003 Jun; 41(6):261-6. PubMed ID: 12816178
[TBL] [Abstract][Full Text] [Related]
47. Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib.
Gottesdiener K; Agrawal N; Porras A; Wong P; Rogers JD; Gertz BJ; Redfern JS; Marbury T
Am J Ther; 2003; 10(4):252-8. PubMed ID: 12845388
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function.
Wong SL; Menacherry S; Mulford D; Schmitz PJ; Locke C; Granneman GR
Eur J Clin Pharmacol; 1997; 52(3):223-7. PubMed ID: 9218930
[TBL] [Abstract][Full Text] [Related]
49. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses.
Barbhaiya RH; Shukla UA; Pfeffer M; Pittman KA; Shrotriya R; Laroudie C; Gammans RE
Eur J Clin Pharmacol; 1994; 46(1):41-7. PubMed ID: 7911763
[TBL] [Abstract][Full Text] [Related]
50. The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment.
Blake JC; Palmer JL; Minton NA; Burroughs AK
Br J Clin Pharmacol; 1993 Apr; 35(4):441-3. PubMed ID: 8485026
[TBL] [Abstract][Full Text] [Related]
51. Effect of renal function on risedronate pharmacokinetics after a single oral dose.
Mitchell DY; St Peter JV; Eusebio RA; Pallone KA; Kelly SC; Russell DA; Nesbitt JD; Thompson GA; Powell JH
Br J Clin Pharmacol; 2000 Mar; 49(3):215-22. PubMed ID: 10718776
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment.
Younis IR; Nelson C; Weber EJ; Qin AR; Watkins TR; Othman AA
J Clin Pharmacol; 2024 Jul; 64(7):878-886. PubMed ID: 38520128
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics and safety of a single oral dose of once-daily alfuzosin, 10 mg, in male subjects with mild to severe renal impairment.
Marbury TC; Blum RA; Rauch C; Pinquier JL
J Clin Pharmacol; 2002 Dec; 42(12):1311-7. PubMed ID: 12463725
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of etoricoxib in patients with hepatic impairment.
Agrawal NG; Rose MJ; Matthews CZ; Woolf EJ; Porras AG; Geer LA; Larson PJ; Cote J; Dilzer SC; Lasseter KC; Alam I; Petty KJ; Gottesdiener KM
J Clin Pharmacol; 2003 Oct; 43(10):1136-48. PubMed ID: 14517196
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction.
Heald AE; Hsyu PH; Yuen GJ; Robinson P; Mydlow P; Bartlett JA
Antimicrob Agents Chemother; 1996 Jun; 40(6):1514-9. PubMed ID: 8726029
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics of cetamolol in hypertensive patients with normal and compromised renal function.
Skoutakis VA; Acchiardo SA; Carter CA; Ingebretsen CG; Klausner MA; Lee DK; Kraml M
J Clin Pharmacol; 1988 May; 28(5):467-76. PubMed ID: 2899095
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose.
Lecaillon JB; Dubois JP; Coppens H; Darragon T; Reumond G; Pozet N; Traeger J; Lambrey G
Eur J Drug Metab Pharmacokinet; 1990; 15(3):231-7. PubMed ID: 2253654
[TBL] [Abstract][Full Text] [Related]
58. The effects of hepatic impairment on the pharmacokinetics of doxazosin.
Penenberg D; Chung M; Walmsley P; Vashi V
J Clin Pharmacol; 2000 Jan; 40(1):67-73. PubMed ID: 10631624
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency.
Müller FO; Terblanchè J; Schall R; van Zyl Smit R; Tucker T; Marais K; Groenewoud G; Porchet HC; Weiner M; Hawarden D
Br J Clin Pharmacol; 1997 Oct; 44(4):335-41. PubMed ID: 9354307
[TBL] [Abstract][Full Text] [Related]
60. Clinical pharmacokinetics of oral buspirone in patients with impaired renal function.
Caccia S; Vigano GL; Mingardi G; Garattini S; Gammans RE; Placchi M; Mayol RF; Pfeffer M
Clin Pharmacokinet; 1988 Mar; 14(3):171-7. PubMed ID: 3370902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
